Cargando…

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer

PD-1 expression in peripheral blood T-cells has been reported in several kinds of cancers, including lung cancer. However, the relationship between PD-1 expression in peripheral blood T-cells and prognosis after treatment with a cancer vaccine has not been reported. To elucidate this relationship, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waki, Kayoko, Yamada, Teppei, Yoshiyama, Koichi, Terazaki, Yasuhiro, Sakamoto, Shinjiro, Matsueda, Satoko, Komatsu, Nobukazu, Sugawara, Shunichi, Takamori, Shinzo, Itoh, Kyogo, Yamada, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462362/ https://www.ncbi.nlm.nih.gov/pubmed/25117757 http://dx.doi.org/10.1111/cas.12502

Ejemplares similares

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer
por: Waki, Kayoko, et al.
Publicado: (2021)

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017)

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
por: Waki, Kayoko, et al.
Publicado: (2017)

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016)

Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Surgical resection of extramedullary haematopoiesis in the posterior mediastinum
por: Matsumoto, Ryoichi, et al.
Publicado: (2018)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Blockade of high mobility group box 1 augments antitumor T‐cell response induced by peptide vaccination as a co‐adjuvant
por: Waki, Kayoko, et al.
Publicado: (2016)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen‐specific T cells
por: Waki, Kayoko, et al.
Publicado: (2022)

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
por: Muroya, Daisuke, et al.
Publicado: (2016)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans
por: Espinoza, J. Luis, et al.
Publicado: (2017)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

Survival after initial lung metastasectomy for metastatic colorectal cancer in the modern chemotherapeutic era
por: Yokoyama, Shintaro, et al.
Publicado: (2017)

Temporary airway stenting for giant anterior mediastinal tumor biopsy: Two case reports
por: Matsumoto, Ryoichi, et al.
Publicado: (2019)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Macrophages and Cell-Cell Spread of HIV-1
por: Waki, Kayoko, et al.
Publicado: (2010)

The Search for the Pathogenic T Cells in the Joint of Rheumatoid Arthritis: Which T-Cell Subset Drives Autoimmune Inflammation?
por: Yamada, Hisakata
Publicado: (2023)

Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth
por: Yokomizo, Kanako, et al.
Publicado: (2022)

Mouse Homologue of the Human SART3 Gene Encoding Tumor‐rejection Antigen
por: Harada, Kenji, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_mv9hbap75181r8vcfq53vj9f9c